Evidence map›Paper›PMID 22969422›Full record

ReviewPLoS pathogens2012

Antifungal drug discovery: something old and something new.

Arielle Butts, Damian J Krysan

Abstract readReview
In one paragraph

Review in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Unveiling novel insights: geraniol's enhanced anti-candida efficacy and mechanistic innovations against multidrug-resistant candida strains.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  6. Review
  7. Article
  8. Antifungal therapy ofBiofilm · 2023
    Article
  9. Article
  10. Searching for new antifungals for the treatment of cryptococcosis.Revista da Sociedade Brasileira de Medicina Tropical · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021
    Review
  17. Antibiotics (Basel, Switzerland) · 2020
    Article
  18. Article
  19. Review
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Arielle ButtsDepartment of Chemistry, University of Rochester, Rochester, New York, United States of America.
Damian J Krysan

Funding

Phosphoinositide-dependent kinase-1 as an antifungal drug targetR01AI097142 · NIAID · UNIVERSITY OF ROCHESTER · PI KRYSAN, DAMIAN J · 2012 to 2016
$1.9M
Discovery and evaluation of fungicidal anti-cryptococcal moleculesR01AI091422 · NIAID · UNIVERSITY OF ROCHESTER · PI KRYSAN, DAMIAN J · 2010 to 2012
$1.2M
NIAID NIH HHS AI091422NIAID NIH HHS AI097142NIAID NIH HHS R01 AI091422NIAID NIH HHS R01 AI097142NIAID NIH HHS R01 AI1075033
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antifungal AgentsCell WallDrug DiscoveryDrug RepositioningHealth Services Needs and DemandHumansMicrobial Sensitivity TestsModels, BiologicalMolecular Targeted TherapyMycosesAntifungal Agents

Identifiers

PMID22969422
PMCPMC3435257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.